Roche Acquires PathAI to Expand Digital Pathology Business

Swiss healthcare giant Roche has signed a definitive merger agreement to acquire U.S.-based artificial intelligence pathology company PathAI, strengthening its position in the rapidly growing digital pathology and precision diagnostics market.

The companies announced that PathAI will become part of Roche’s Diagnostics division once the transaction closes, which is expected during the second half of 2026. Financial terms of the acquisition were not disclosed.

The deal builds on an existing partnership between Roche and PathAI that began in 2021 and expanded significantly in 2024 to include the development of AI-enabled companion diagnostic algorithms. Roche said the acquisition would allow it to further integrate artificial intelligence technologies into pathology workflows and accelerate innovation in cancer diagnostics and precision medicine.

Digital pathology is increasingly transforming traditional laboratory processes by converting physical tissue slides into high-resolution digital images that can be analyzed using AI-powered software. The technology is designed to help pathologists automate time-consuming manual tasks, improve diagnostic accuracy, and provide faster results for patients.

Roche Diagnostics Chief Executive Officer Matt Sause said the acquisition supports the company’s long-term strategy of advancing precision oncology and AI-driven healthcare solutions.

“Digital pathology has the potential to improve precision diagnosis of cancer and enable physicians to offer better tailored treatment regimens,” Sause said in a statement. “Bringing PathAI into Roche Diagnostics will allow us to combine their best-in-class digital pathology tools with our leading oncology diagnosis platforms to deliver better insights for physicians and potentially better outcomes for patients worldwide.”

Founded in the United States, PathAI has developed a range of AI-powered pathology technologies used by laboratories and biopharmaceutical companies. Its AISight IMS software platform integrates advanced image analysis and workflow management capabilities aimed at improving efficiency inside digital pathology laboratories.

Roche said it intends to scale the AISight platform globally as demand for digital pathology solutions continues to increase across hospitals, diagnostic laboratories, and pharmaceutical research organizations.

PathAI Chief Executive Officer and Co-Founder Andy Beck described the acquisition as a major milestone for the company.

“Joining forces with Roche marks a new era for PathAI, enabling us to realise our mission of improving patient outcomes through AI-powered pathology at unprecedented scale and speed,” Beck said. “Roche’s global infrastructure and expertise will bring our digital diagnostics technology to patients worldwide.”

Beyond pathology workflows, Roche believes the acquisition will also strengthen its biopharma services and companion diagnostics business. PathAI’s expertise in AI-driven clinical trial support, biomarker discovery, and translational research is expected to complement Roche’s established capabilities in precision medicine.

The combined technologies could help pharmaceutical companies identify new biomarkers, uncover potential drug targets, and develop more advanced diagnostic tools to support targeted therapies.

The acquisition reflects growing investment across the healthcare sector in artificial intelligence technologies designed to improve diagnostics, accelerate drug development, and enable more personalized treatment strategies. As healthcare systems increasingly adopt digital solutions, companies such as Roche are seeking to position themselves at the forefront of AI-enabled diagnostics and precision medicine innovation.